{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:46:03Z","timestamp":1775886363166,"version":"3.50.1"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01504-y","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:59:06Z","timestamp":1775879946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-2844","authenticated-orcid":false,"given":"Hennie G.","family":"Raterman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Haugeberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Morales","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Vidal","family":"Neira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leith","family":"Zakraoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Zerbini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo D.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the IOF Osteoimmunology working group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"5","key":"1504_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00223-017-0373-1","volume":"102","author":"JH Shim","year":"2018","unstructured":"Shim JH, Stavre Z, Gravallese EM (2018) Bone loss in Rheumatoid Arthritis: basic mechanisms and clinical implications. Calcif Tissue Int 102(5):533\u2013546","journal-title":"Calcif Tissue Int"},{"issue":"14","key":"1504_CR2","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1080\/14656566.2020.1787381","volume":"21","author":"HG Raterman","year":"2020","unstructured":"Raterman HG, Bultink IE, Lems WF (2020) Osteoporosis in patients with Rheumatoid Arthritis: an update in epidemiology, pathogenesis, and fracture prevention. Expert Opin Pharmacother 21(14):1725\u20131737","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1504_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.10747","volume":"48","author":"PG Conaghan","year":"2003","unstructured":"Conaghan PG, O\u2019Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW et al (2003) Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 48(1):64\u201371","journal-title":"Arthritis Rheum"},{"issue":"8914","key":"1504_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0140-6736(94)91049-9","volume":"344","author":"AK Gough","year":"1994","unstructured":"Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early Rheumatoid Arthritis. Lancet 344(8914):23\u201327","journal-title":"Lancet"},{"issue":"2","key":"1504_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/rheumatology\/39.2.122","volume":"39","author":"DL Scott","year":"2000","unstructured":"Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J et al (2000) The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 39(2):122\u2013132","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1504_CR6","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/ard.2008.106484","volume":"68","author":"G Haugeberg","year":"2009","unstructured":"Haugeberg G, Conaghan PG, Quinn M, Emery P (2009) Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68(12):1898\u20131901","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1504_CR7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/ard.2005.043869","volume":"65","author":"G Haugeberg","year":"2006","unstructured":"Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z et al (2006) Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65(6):736\u2013740","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1504_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00198-025-07397-1","volume":"36","author":"JA Kanis","year":"2025","unstructured":"Kanis JA, Johansson H, McCloskey EV, Liu E, Schini M, Vandenput L et al (2025) Rheumatoid arthritis and subsequent fracture risk: an individual person meta-analysis to update FRAX. Osteoporos Int 36(4):653\u2013671","journal-title":"Osteoporos Int"},{"issue":"4","key":"1504_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/archinte.164.4.420","volume":"164","author":"RE Orstavik","year":"2004","unstructured":"Orstavik RE, Haugeberg G, Mowinckel P, Hoiseth A, Uhlig T, Falch JA et al (2004) Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. Arch Intern Med 164(4):420\u2013425","journal-title":"Arch Intern Med"},{"issue":"10","key":"1504_CR10","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1002\/art.22117","volume":"54","author":"TP van Staa","year":"2006","unstructured":"van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with Rheumatoid Arthritis. Arthritis Rheum 54(10):3104\u20133112","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1504_CR11","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00198-018-4473-1","volume":"29","author":"S Jin","year":"2018","unstructured":"Jin S, Hsieh E, Peng L, Yu C, Wang Y, Wu C et al (2018) Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int 29(6):1263\u20131275","journal-title":"Osteoporos Int"},{"issue":"11","key":"1504_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","volume":"8","author":"G Schett","year":"2012","unstructured":"Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8(11):656\u2013664","journal-title":"Nat Rev Rheumatol"},{"issue":"6812","key":"1504_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/35046196","volume":"408","author":"JR Arron","year":"2000","unstructured":"Arron JR, Choi Y (2000) Bone versus immune system. Nature 408(6812):535\u2013536","journal-title":"Nature"},{"issue":"4","key":"1504_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nri2062","volume":"7","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7(4):292\u2013304","journal-title":"Nat Rev Immunol"},{"key":"1504_CR15","doi-asserted-by":"publisher","first-page":"116468","DOI":"10.1016\/j.bone.2022.116468","volume":"162","author":"D Andreev","year":"2022","unstructured":"Andreev D, Kachler K, Schett G, Bozec A (2022) Rheumatoid arthritis and osteoimmunology: the adverse impact of a deregulated immune system on bone metabolism. Bone 162:116468","journal-title":"Bone"},{"issue":"1","key":"1504_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ard-2022-223365","volume":"82","author":"A Kerschbaumer","year":"2023","unstructured":"Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R et al (2023) Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82(1):95\u2013106","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1504_CR17","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52(11):3381\u20133390","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1504_CR18","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard-2023-224116","volume":"82","author":"M Ostergaard","year":"2023","unstructured":"Ostergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordstrom DC et al (2023) Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial. Ann Rheum Dis 82(10):1286\u20131295","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"1504_CR19","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.3390\/ijms20235867","volume":"20","author":"G Adami","year":"2019","unstructured":"Adami G, Fassio A, Rossini M, Caimmi C, Giollo A, Orsolini G et al (2019) Osteoporosis in rheumatic diseases. Int J Mol Sci 20(23):5867","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1504_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11914-013-0183-y","volume":"12","author":"R Baum","year":"2014","unstructured":"Baum R, Gravallese EM (2014) Impact of inflammation on the osteoblast in rheumatic diseases. Curr Osteoporos Rep 12(1):9\u201316","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"1504_CR21","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40520-023-02432-9","volume":"35","author":"OD Messina","year":"2023","unstructured":"Messina OD, Vidal M, Adami G, Vidal LF, Clark P, Torres JAM et al (2023) Chronic arthritides and bone structure: focus on rheumatoid arthritis-an update. Aging Clin Exp Res 35(7):1405\u20131416","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"1504_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cyto.2004.02.001","volume":"26","author":"T Ma","year":"2004","unstructured":"Ma T, Miyanishi K, Suen A, Epstein NJ, Tomita T, Smith RL et al (2004) Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha. Cytokine 26(3):138\u2013144","journal-title":"Cytokine"},{"issue":"2","key":"1504_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.191.2.275","volume":"191","author":"K Kobayashi","year":"2000","unstructured":"Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S et al (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF\/RANKL-RANK interaction. J Exp Med 191(2):275\u2013286","journal-title":"J Exp Med"},{"issue":"1","key":"1504_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/jbmr.5650110113","volume":"11","author":"S Kotake","year":"1996","unstructured":"Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I et al (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11(1):88\u201395","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1504_CR25","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106(12):1481\u20131488","journal-title":"J Clin Invest"},{"issue":"1","key":"1504_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.13188","volume":"194","author":"N Komatsu","year":"2018","unstructured":"Komatsu N, Takayanagi H (2018) Immune-bone interplay in the structural damage in rheumatoid arthritis. Clin Exp Immunol 194(1):1\u20138","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"1504_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00774-020-01191-1","volume":"39","author":"H Takayanagi","year":"2021","unstructured":"Takayanagi H (2021) RANKL as the master regulator of osteoclast differentiation. J Bone Miner Metab 39(1):13\u201318","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"1504_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41584-025-01323-9","volume":"22","author":"M Rauner","year":"2026","unstructured":"Rauner M, Bozec A (2026) Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis. Nat Rev Rheumatol 22(1):42\u201361","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"1504_CR29","doi-asserted-by":"publisher","first-page":"e0138189","DOI":"10.1371\/journal.pone.0138189","volume":"10","author":"J Xiong","year":"2015","unstructured":"Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V et al (2015) Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS ONE 10(9):e0138189","journal-title":"PLoS ONE"},{"key":"1504_CR30","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3389\/fimmu.2019.02925","volume":"10","author":"A Marahleh","year":"2019","unstructured":"Marahleh A, Kitaura H, Ohori F, Kishikawa A, Ogawa S, Shen WR et al (2019) TNF-alpha directly enhances osteocyte RANKL expression and promotes osteoclast formation. Front Immunol 10:2925","journal-title":"Front Immunol"},{"issue":"3","key":"1504_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/0004563218759371","volume":"55","author":"JS Kenkre","year":"2018","unstructured":"Kenkre JS, Bassett J (2018) The bone remodelling cycle. Ann Clin Biochem 55(3):308\u2013327","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"1504_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5312\/wjo.v4.i1.1","volume":"4","author":"S Tanaka","year":"2013","unstructured":"Tanaka S (2013) Regulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways. World J Orthop 4(1):1\u20136","journal-title":"World J Orthop"},{"issue":"5","key":"1504_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/ar431","volume":"4","author":"N Udagawa","year":"2002","unstructured":"Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T (2002) The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 4(5):281\u2013289","journal-title":"Arthritis Res"},{"key":"1504_CR34","doi-asserted-by":"publisher","first-page":"115628","DOI":"10.1016\/j.bone.2020.115628","volume":"141","author":"JM Delaisse","year":"2020","unstructured":"Delaisse JM, Andersen TL, Kristensen HB, Jensen PR, Andreasen CM, Soe K (2020) Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. Bone 141:115628","journal-title":"Bone"},{"key":"1504_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.intimp.2018.04.019","volume":"59","author":"Y Ma","year":"2018","unstructured":"Ma Y, Zhang X, Wang M, Xia Q, Yang J, Wu M et al (2018) The serum level of Dickkopf-1 in patients with rheumatoid arthritis: A systematic review and meta-analysis. Int Immunopharmacol 59:227\u2013232","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1504_CR36","first-page":"77","volume":"33","author":"M Rossini","year":"2015","unstructured":"Rossini M, Viapiana O, Adami S, Fracassi E, Idolazzi L, Dartizio C et al (2015) In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol 33(1):77\u201383","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"1504_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jbspin.2010.03.002","volume":"77","author":"B Le Goff","year":"2010","unstructured":"Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y (2010) Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 77(3):201\u2013205","journal-title":"Joint Bone Spine"},{"issue":"1","key":"1504_CR38","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/25785826.2023.2220931","volume":"47","author":"K Yokota","year":"2024","unstructured":"Yokota K (2024) Osteoclast differentiation in rheumatoid arthritis. Immunol Med 47(1):6\u201311","journal-title":"Immunol Med"},{"issue":"4","key":"1504_CR39","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1159\/000465455","volume":"41","author":"Q Wu","year":"2017","unstructured":"Wu Q, Zhou X, Huang D, Ji Y, Kang F (2017) IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting JAK2 and RANKL activity in vitro. Cell Physiol Biochem 41(4):1360\u20131369","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"1504_CR40","doi-asserted-by":"publisher","first-page":"101611","DOI":"10.1016\/j.beem.2021.101611","volume":"36","author":"G Adami","year":"2022","unstructured":"Adami G (2022) Regulation of bone mass in inflammatory diseases. Best Pract Res Clin Endocrinol Metab 36(2):101611","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"1504_CR41","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00223-012-9665-7","volume":"92","author":"O Viapiana","year":"2013","unstructured":"Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S et al (2013) Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 92(4):324\u2013329","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1504_CR42","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3899\/jrheum.100829","volume":"38","author":"M Rossini","year":"2011","unstructured":"Rossini M, Bagnato G, Frediani B, Iagnocco A, La Montagna G, Minisola G et al (2011) Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis. J Rheumatol 38(6):997\u20131002","journal-title":"J Rheumatol"},{"issue":"2","key":"1504_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/03009742.2021.1917161","volume":"51","author":"GA Versteeg","year":"2022","unstructured":"Versteeg GA, Steunebrink L, Vonkeman HE, Ten Klooster PM, Van Der Bijl AE, Van De Laar M (2022) Early radiological progression remains associated with long-term joint damage in real-world rheumatoid arthritis patients treated to the target of remission. Scand J Rheumatol 51(2):87\u201396","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"1504_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/rheumatology\/keu284","volume":"54","author":"V Navarro-Compan","year":"2015","unstructured":"Navarro-Compan V, Landewe R, Provan SA, Odegard S, Uhlig T, Kvien TK et al (2015) Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. Rheumatology (Oxford) 54(1):83\u201390","journal-title":"Rheumatology (Oxford)"},{"key":"1504_CR45","doi-asserted-by":"publisher","first-page":"117250","DOI":"10.1016\/j.bone.2024.117250","volume":"189","author":"K Watanabe","year":"2024","unstructured":"Watanabe K, Chiba K, Shiraishi K, Iida T, Iwamoto N, Yonekura A et al (2024) Microarchitectural analysis of the metacarpophalangeal joint using HR-pQCT in patients with rheumatoid arthritis: a comparison with healthy controls. Bone 189:117250","journal-title":"Bone"},{"issue":"1","key":"1504_CR46","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13075-017-1430-x","volume":"19","author":"T Shimizu","year":"2017","unstructured":"Shimizu T, Choi HJ, Heilmeier U, Tanaka M, Burghardt AJ, Gong J et al (2017) Assessment of 3-month changes in bone microstructure under anti-TNFalpha therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT). Arthritis Res Ther 19(1):222","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1504_CR47","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3899\/jrheum.191391","volume":"48","author":"S Finzel","year":"2021","unstructured":"Finzel S, Manske SL, Barnabe CCM, Burghardt AJ, Marotte H, Scharmga A et al (2021) Reliability and change in erosion measurements by high-resolution peripheral quantitative computed tomography in a longitudinal dataset of rheumatoid arthritis patients. J Rheumatol 48(3):348\u2013351","journal-title":"J Rheumatol"},{"issue":"3","key":"1504_CR48","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/rheumatology\/keab446","volume":"61","author":"R Klose-Jensen","year":"2022","unstructured":"Klose-Jensen R, Therkildsen J, Blavnsfeldt AG, Langdahl BL, Zejden A, Thygesen J et al (2022) Diagnostic accuracy of high-resolution peripheral quantitative computed tomography and X-ray for classifying erosive rheumatoid arthritis. Rheumatology (Oxford) 61(3):963\u2013973","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1504_CR49","doi-asserted-by":"publisher","first-page":"e0265833","DOI":"10.1371\/journal.pone.0265833","volume":"17","author":"K Shiraishi","year":"2022","unstructured":"Shiraishi K, Chiba K, Watanabe K, Oki N, Iwamoto N, Amano S et al (2022) Analysis of bone erosions in rheumatoid arthritis using HR-pQCT: Development of a measurement algorithm and assessment of longitudinal changes. PLoS ONE 17(4):e0265833","journal-title":"PLoS ONE"},{"issue":"1","key":"1504_CR50","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13075-022-02957-w","volume":"24","author":"N Iwamoto","year":"2022","unstructured":"Iwamoto N, Chiba K, Sato S, Shiraishi K, Watanabe K, Oki N et al (2022) Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study. Arthritis Res Ther 24(1):264","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1504_CR51","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/annrheumdis-2021-219846","volume":"80","author":"H So","year":"2021","unstructured":"So H, Cheng IT, Lau SL, Chow E, Lam T, Hung VW et al (2021) Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 80(8):981\u2013988","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1504_CR52","doi-asserted-by":"publisher","first-page":"27673","DOI":"10.1038\/s41598-024-77392-9","volume":"14","author":"N Iwamoto","year":"2024","unstructured":"Iwamoto N, Chiba K, Sato S, Tashiro S, Shiraishi K, Watanabe K et al (2024) Preferable effect of CTLA4-Ig on both bone erosion and bone microarchitecture in rheumatoid arthritis revealed by HR-pQCT. Sci Rep 14(1):27673","journal-title":"Sci Rep"},{"issue":"1","key":"1504_CR53","doi-asserted-by":"publisher","first-page":"105812","DOI":"10.1016\/j.jbspin.2024.105812","volume":"92","author":"J Therkildsen","year":"2025","unstructured":"Therkildsen J, Klose-Jensen R, Hanel M, Langdahl BL, Thomsen JS, Manske SL et al (2025) Detecting new erosions in rheumatoid arthritis over one year - Radiography and high-resolution computed tomography of finger joints. Joint Bone Spine 92(1):105812","journal-title":"Joint Bone Spine"},{"issue":"5","key":"1504_CR54","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299\u20131309","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1504_CR55","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clinic Med 10(1):152","journal-title":"J Clinic Med"},{"issue":"2","key":"1504_CR56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/mr\/roab022","volume":"32","author":"S Tanaka","year":"2022","unstructured":"Tanaka S, Kobayashi M, Saito K, Takita A (2022) Impact of Denosumab discontinuation on changes in bone mineral density and bone erosion in rheumatoid arthritis patients. Mod Rheumatol 32(2):284\u2013291","journal-title":"Mod Rheumatol"},{"issue":"6","key":"1504_CR57","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1083\/jcb.200611083","volume":"176","author":"W Zou","year":"2007","unstructured":"Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ et al (2007) Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 176(6):877\u2013888","journal-title":"J Cell Biol"},{"issue":"3","key":"1504_CR58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1084\/jem.20051123","volume":"202","author":"A Vignery","year":"2005","unstructured":"Vignery A (2005) Macrophage fusion: the making of osteoclasts and giant cells. J Exp Med 202(3):337\u2013340","journal-title":"J Exp Med"},{"issue":"16","key":"1504_CR59","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1073\/pnas.0401602101","volume":"101","author":"A Mocsai","year":"2004","unstructured":"Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC et al (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 101(16):6158\u20136163","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1504_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.30081","volume":"63","author":"J Sokolove","year":"2011","unstructured":"Sokolove J, Zhao X, Chandra PE, Robinson WH (2011) Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fcgamma receptor. Arthritis Rheum 63(1):53\u201362","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1504_CR61","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","volume":"75","author":"A Krishnamurthy","year":"2016","unstructured":"Krishnamurthy A, Joshua V, Haj Hensvold A, Jin T, Sun M, Vivar N et al (2016) Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis 75(4):721\u2013729","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1504_CR62","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/ard.2009.113092","volume":"69","author":"SW Syversen","year":"2010","unstructured":"Syversen SW, Goll GL, van der Heijde D, Landewe R, Lie BA, Odegard S et al (2010) Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 69(2):345\u2013351","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1504_CR63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.131177","volume":"42","author":"RT Alarcon","year":"2015","unstructured":"Alarcon RT, Fernandes AR, Laurindo IM, Bertolo MB, Pinheiro GC, Andrade LE (2015) Characterization of cumulative joint damage patterns in patients with rheumatoid arthritis: a clinical, serological, and gene polymorphism perspective. J Rheumatol 42(3):405\u2013412","journal-title":"J Rheumatol"},{"issue":"8","key":"1504_CR64","doi-asserted-by":"publisher","first-page":"e0202583","DOI":"10.1371\/journal.pone.0202583","volume":"13","author":"C Regueiro","year":"2018","unstructured":"Regueiro C, Ortiz AM, Boveda MD, Castaneda S, Gonzalez-Alvaro I, Gonzalez A (2018) Association of high titers of anti-carbamylated protein antibodies with decreased bone mineral density in early arthritis patients. PLoS ONE 13(8):e0202583","journal-title":"PLoS ONE"},{"issue":"9","key":"1504_CR65","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/ard.2003.014233","volume":"63","author":"K Forslind","year":"2004","unstructured":"Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B, Group BS (2004) Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63(9):1090\u20131095","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1504_CR66","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.semarthrit.2018.05.001","volume":"48","author":"J Yue","year":"2018","unstructured":"Yue J, Griffith JF, Xu J, Xiao F, Shi L, Wang D et al (2018) Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: an HR-pQCT study. Semin Arthritis Rheum 48(3):374\u2013383","journal-title":"Semin Arthritis Rheum"},{"key":"1504_CR67","doi-asserted-by":"publisher","first-page":"1759720X2311745","DOI":"10.1177\/1759720X231174534","volume":"15","author":"G Adami","year":"2023","unstructured":"Adami G, Fassio A, Pistillo F, Benini C, Viapiana O, Rossini M et al (2023) Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs). Ther Adv Musculoskelet Dis. 15:1759720X231174534","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"4","key":"1504_CR68","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10067-020-05385-w","volume":"40","author":"L Ji","year":"2021","unstructured":"Ji L, Xie W, Li G, Zhang Z (2021) Maintenance to target was associated with radiological outcomes in patients with rheumatoid arthritis: a real-world observational cohort study. Clin Rheumatol 40(4):1307\u20131315","journal-title":"Clin Rheumatol"},{"issue":"9","key":"1504_CR69","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1093\/rheumatology\/kead021","volume":"62","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Landewe R, van der Heijde D, Sepriano A, FitzGerald O, Ostergaard M et al (2023) Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford) 62(9):2989\u20132997","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1504_CR70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/ard-2023-224814","volume":"83","author":"SL Heckert","year":"2024","unstructured":"Heckert SL, Maassen JM, le Cessie S, Goekoop-Ruiterman YPM, Guler-Yuksel M, Lems W et al (2024) Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort. Ann Rheum Dis 83(2):161\u2013168","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1504_CR71","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3109\/03009749609065648","volume":"25","author":"M Hansen","year":"1996","unstructured":"Hansen M, Florescu A, Stoltenberg M, Podenphant J, Pedersen-Zbinden B, Horslev-Petersen K et al (1996) Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. Scand J Rheumatol 25(6):367\u2013376","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"1504_CR72","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/rheumatology\/keq125","volume":"49","author":"M Hoff","year":"2010","unstructured":"Hoff M, Boyesen P, Haugeberg G, Vis M, Woolf AD, Havaardsholm EA et al (2010) High disease activity is a predictor of cortical hand bone loss in post-menopausal patients with established rheumatoid arthritis: a 5-year multicentre longitudinal study. Rheumatology (Oxford) 49(9):1676\u20131682","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1504_CR73","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/rheumatology\/keu173","volume":"53","author":"Q Hong","year":"2014","unstructured":"Hong Q, Xu J, Xu S, Lian L, Zhang M, Ding C (2014) Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology (Oxford) 53(11):1994\u20132001","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1504_CR74","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00198-019-04906-x","volume":"30","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int 30(6):1145\u20131156","journal-title":"Osteoporos Int"},{"key":"1504_CR75","doi-asserted-by":"publisher","first-page":"116958","DOI":"10.1016\/j.bone.2023.116958","volume":"179","author":"G Adami","year":"2024","unstructured":"Adami G, Gatti D, Rossini M, Giollo A, Gatti M, Bertoldo F et al (2024) Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: an analysis on a nation-wide database. Bone 179:116958","journal-title":"Bone"},{"issue":"1","key":"1504_CR76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00223-017-0253-8","volume":"101","author":"G Orsolini","year":"2017","unstructured":"Orsolini G, Caimmi C, Viapiana O, Idolazzi L, Fracassi E, Gatti D et al (2017) Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients. Calcif Tissue Int 101(1):17\u201323","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1504_CR77","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/art.41623","volume":"73","author":"J Amkreutz","year":"2021","unstructured":"Amkreutz J, de Moel EC, Theander L, Willim M, Heimans L, Nilsson JA et al (2021) Association between bone mineral density and autoantibodies in patients with rheumatoid arthritis. Arthritis Rheumatol 73(6):921\u2013930","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1504_CR78","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F et al (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73(5):854\u2013860","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1504_CR79","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s11926-013-0366-7","volume":"15","author":"R Kocijan","year":"2013","unstructured":"Kocijan R, Harre U, Schett G (2013) ACPA and bone loss in rheumatoid arthritis. Curr Rheumatol Rep 15(10):366","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"1504_CR80","doi-asserted-by":"publisher","first-page":"R216","DOI":"10.1186\/ar3195","volume":"12","author":"M Rossini","year":"2010","unstructured":"Rossini M, Maddali Bongi S, La Montagna G, Minisola G, Malavolta N, Bernini L et al (2010) Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther 12(6):R216","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1504_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ero.2025.02.001","volume":"1","author":"WF Lems","year":"2025","unstructured":"Lems WF, Bijlsma JWJ (2025) Vitamin D supplementation: still a challenge for rheumatologists! EULAR Rheumatol Open 1(1):1\u20133","journal-title":"EULAR Rheumatol Open"},{"key":"1504_CR82","doi-asserted-by":"publisher","first-page":"e066452","DOI":"10.1136\/bmj-2021-066452","volume":"376","author":"J Hahn","year":"2022","unstructured":"Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V et al (2022) Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ 376:e066452","journal-title":"BMJ"},{"issue":"2","key":"1504_CR83","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Gatti D, Adami S (2013) Involvement of WNT\/beta-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93(2):121\u2013132","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1504_CR84","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156\u2013163","journal-title":"Nat Med"},{"key":"1504_CR85","doi-asserted-by":"publisher","first-page":"1291727","DOI":"10.3389\/fimmu.2023.1291727","volume":"14","author":"G Adami","year":"2023","unstructured":"Adami G, Fassio A, Rossini M, Benini C, Bixio R, Rotta D et al (2023) Machine learning to characterize bone biomarkers profile in rheumatoid arthritis. Front Immunol 14:1291727","journal-title":"Front Immunol"},{"issue":"5","key":"1504_CR86","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2010-2552","volume":"96","author":"D Gatti","year":"2011","unstructured":"Gatti D, Viapiana O, Idolazzi L, Fracassi E, Rossini M, Adami S (2011) The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. J Clin Endocrinol Metab 96(5):1555\u20131559","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"1504_CR87","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00393-021-01091-3","volume":"82","author":"YM Mao","year":"2023","unstructured":"Mao YM, Liao T, Ye QL, Wu GC, Zhang Q, Tao SS et al (2023) Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis. Z Rheumatol 82(Suppl 1):51\u201358","journal-title":"Z Rheumatol"},{"issue":"10","key":"1504_CR88","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/jbmr.3209","volume":"32","author":"M Rossini","year":"2017","unstructured":"Rossini M, Adami G, Viapiana O, Idolazzi L, Orsolini G, Fassio A et al (2017) Osteoporosis: An independent determinant of bone erosions in rheumatoid arthritis? J Bone Miner Res 32(10):2142\u20132143","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1504_CR89","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/1573397112666160909094403","volume":"13","author":"AP Anandarajah","year":"2017","unstructured":"Anandarajah AP, El-Taha M, Peng C, Ritchlin CT (2017) The relationship between focal and generalized bone loss in rheumatoid arthritis. Curr Rheumatol Rev 13(2):152\u2013157","journal-title":"Curr Rheumatol Rev"},{"issue":"6","key":"1504_CR90","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/art.24551","volume":"60","author":"DH Solomon","year":"2009","unstructured":"Solomon DH, Finkelstein JS, Shadick N, LeBoff MS, Winalski CS, Stedman M et al (2009) The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 60(6):1624\u20131631","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1504_CR91","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2174\/1573397115666190716120127","volume":"16","author":"MH Elshahaly","year":"2020","unstructured":"Elshahaly MH, Gad KA (2020) The utility of radiographic focal erosions of hands or feet in predicting DXA-defined osteoporosis of the hip in patients with rheumatoid arthritis. Curr Rheumatol Rev 16(1):74\u201378","journal-title":"Curr Rheumatol Rev"},{"issue":"1","key":"1504_CR92","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1504_CR93","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/art.10996","volume":"49","author":"MC Lodder","year":"2003","unstructured":"Lodder MC, Haugeberg G, Lems WF, Uhlig T, Orstavik RE, Kostense PJ et al (2003) Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. Arthritis Rheum 49(2):209\u2013215","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1504_CR94","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/art.11292","volume":"48","author":"M Vis","year":"2003","unstructured":"Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de Koning MH et al (2003) Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. Arthritis Rheum 48(10):2996\u20132997","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1504_CR95","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ et al (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65(11):1495\u20131499","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1504_CR96","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","volume":"28","author":"CAF Zerbini","year":"2017","unstructured":"Zerbini CAF, Clark P, Mendez-Sanchez L, Pereira RMR, Messina OD, Una CR et al (2017) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28(2):429\u2013446","journal-title":"Osteoporos Int"},{"issue":"3","key":"1504_CR97","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/rheumatology\/kes320","volume":"52","author":"CL Krieckaert","year":"2013","unstructured":"Krieckaert CL, Nurmohamed MT, Wolbink G, Lems WF (2013) Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford) 52(3):547\u2013553","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1504_CR98","doi-asserted-by":"publisher","first-page":"e003919","DOI":"10.1136\/rmdopen-2023-003919","volume":"10","author":"I Tronstad","year":"2024","unstructured":"Tronstad I, Hoff M, Horn J, Vikjord SAA, Videm V, Johansson J et al (2024) Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, Norway. RMD Open 10(1):e003919","journal-title":"RMD Open"},{"issue":"9","key":"1504_CR99","first-page":"3416","volume":"25","author":"F Shao","year":"2021","unstructured":"Shao F, Li HC, Wang MJ, Cui CM (2021) Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 25(9):3416\u20133424","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"1504_CR100","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","volume":"82","author":"K Briot","year":"2015","unstructured":"Briot K, Rouanet S, Schaeverbeke T, Etchepare F, Gaudin P, Perdriger A et al (2015) The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine 82(2):109\u2013115","journal-title":"Joint Bone Spine"},{"issue":"5","key":"1504_CR101","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","volume":"53","author":"K Kume","year":"2014","unstructured":"Kume K, Amano K, Yamada S, Kanazawa T, Ohta H, Hatta K et al (2014) The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis. Rheumatology (Oxford) 53(5):900\u2013903","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1504_CR102","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5114\/reum.2022.120756","volume":"60","author":"SG Al Khayyat","year":"2022","unstructured":"Al Khayyat SG, D\u2019Alessandro R, Conticini E, Pierguidi S, Falsetti P, Baldi C et al (2022) Bone-sparing effects of tocilizumab in rheumatoid arthritis: a monocentric observational study. Reumatologia 60(5):326\u2013331","journal-title":"Reumatologia"},{"issue":"11","key":"1504_CR103","doi-asserted-by":"publisher","first-page":"e0188454","DOI":"10.1371\/journal.pone.0188454","volume":"12","author":"YM Chen","year":"2017","unstructured":"Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC et al (2017) Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis. PLoS ONE 12(11):e0188454","journal-title":"PLoS ONE"},{"issue":"5","key":"1504_CR104","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00296-017-3922-z","volume":"38","author":"M Tada","year":"2018","unstructured":"Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T (2018) Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study. Rheumatol Int 38(5):777\u2013784","journal-title":"Rheumatol Int"},{"key":"1504_CR105","doi-asserted-by":"publisher","first-page":"783030","DOI":"10.3389\/fimmu.2021.783030","volume":"12","author":"MH Chen","year":"2021","unstructured":"Chen MH, Yu SF, Chen JF, Chen WS, Liou TL, Chou CT et al (2021) Different effects of biologics on systemic bone loss protection in rheumatoid arthritis: an interim analysis of a three-year longitudinal cohort study. Front Immunol 12:783030","journal-title":"Front Immunol"},{"key":"1504_CR106","doi-asserted-by":"publisher","first-page":"A933","DOI":"10.1136\/annrheumdis-2018-eular.4827","volume":"77","author":"MM Keywani KtW","year":"2018","unstructured":"Keywani KtW MM, Nurmohamed MT, Lems WF, Raterman HG (2018) The arrest of bone mineral density loss at the lumbar spine and hip in patients with active rheumatoid arthritis during rituximab therapy. Ann Rheum Dis 77:A933","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1504_CR107","doi-asserted-by":"publisher","first-page":"e0201527","DOI":"10.1371\/journal.pone.0201527","volume":"13","author":"G Wheater","year":"2018","unstructured":"Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM (2018) Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. PLoS ONE 13(8):e0201527","journal-title":"PLoS ONE"},{"issue":"4","key":"1504_CR108","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5114\/reum.2021.108430","volume":"59","author":"SG Al Khayyat","year":"2021","unstructured":"Al Khayyat SG, Falsetti P, Conticini E, D\u2019Alessandro R, Bellisai F, Gentileschi S et al (2021) Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis - retrospective study. Reumatologia 59(4):206\u2013210","journal-title":"Reumatologia"},{"issue":"530","key":"1504_CR109","doi-asserted-by":"publisher","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","volume":"12","author":"S Adam","year":"2020","unstructured":"Adam S, Simon N, Steffen U, Andes FT, Scholtysek C, M\u00fcller DI, Hueber AJ (2020) JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med 12(530):eaay4447","journal-title":"Sci Transl Med"},{"key":"1504_CR110","doi-asserted-by":"publisher","first-page":"1759720X2211423","DOI":"10.1177\/1759720X221142346","volume":"14","author":"KE Hansen","year":"2022","unstructured":"Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z et al (2022) Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis 14:1759720X221142346","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"8","key":"1504_CR111","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/annrheumdis-2019-215328","volume":"78","author":"G Ozen","year":"2019","unstructured":"Ozen G, Pedro S, Wolfe F, Michaud K (2019) Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis 78(8):1041\u20131047","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1504_CR112","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/RHU.0b013e3181a5679d","volume":"15","author":"KA Coulson","year":"2009","unstructured":"Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH (2009) Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 15(4):155\u2013160","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"1504_CR113","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00223-022-01001-y","volume":"111","author":"B Hauser","year":"2022","unstructured":"Hauser B, Raterman H, Ralston SH, Lems WF (2022) The effect of anti-rheumatic drugs on the skeleton. Calcif Tissue Int 111(5):445\u2013456","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1504_CR114","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/acr.22519","volume":"67","author":"S Siu","year":"2015","unstructured":"Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V et al (2015) Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken) 67(6):754\u2013764","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"1504_CR115","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2008.091611","volume":"68","author":"CA Wijbrandts","year":"2009","unstructured":"Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68(3):373\u2013376","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1504_CR116","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/ard.2009.127787","volume":"70","author":"DA Eekman","year":"2011","unstructured":"Eekman DA, Vis M, Bultink IE, Kuik DJ, Voskuyl AE, Dijkmans BA et al (2011) Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(2):389\u2013390","journal-title":"Ann Rheum Dis"},{"key":"1504_CR117","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/1471-2474-15-289","volume":"15","author":"G Haugeberg","year":"2014","unstructured":"Haugeberg G, Helgetveit KB, Forre O, Garen T, Sommerseth H, Proven A (2014) Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord 15:289","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"1504_CR118","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1007\/s00198-020-05781-7","volume":"32","author":"MJJ Lucassen","year":"2021","unstructured":"Lucassen MJJ, Ter Wee MM, den Uyl D, Konijn NPC, Nurmohamed MT, Voskuyl AE et al (2021) Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. Osteoporos Int 32(7):1441\u20131449","journal-title":"Osteoporos Int"},{"issue":"7","key":"1504_CR119","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.amjmed.2022.01.017","volume":"135","author":"S Abtahi","year":"2022","unstructured":"Abtahi S, Cordtz R, Dreyer L, Driessen JHM, Boonen A, Burden AM (2022) Biological disease-modifying antirheumatic drugs and osteoporotic fracture risk in patients with rheumatoid arthritis: a Danish cohort study. Am J Med 135(7):879\u201388 e3","journal-title":"Am J Med"},{"issue":"9","key":"1504_CR120","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2018-214894","volume":"78","author":"S Finzel","year":"2019","unstructured":"Finzel S, Kraus S, Figueiredo CP, Regensburger A, Kocijan R, Rech J et al (2019) Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis 78(9):1186\u20131191","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1504_CR121","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/1756-185X.13135","volume":"21","author":"Y Kukida","year":"2018","unstructured":"Kukida Y, Kasahara A, Seno T, Inoue T, Sagawa R, Kida T et al (2018) Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands. Int J Rheum Dis 21(9):1678\u20131685","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"1504_CR122","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","volume":"32","author":"A Hamar","year":"2021","unstructured":"Hamar A, Szekanecz Z, Pusztai A, Czokolyova M, Vegh E, Petho Z et al (2021) Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos Int 32(8):1621\u20131629","journal-title":"Osteoporos Int"},{"issue":"5","key":"1504_CR123","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00296-003-0298-z","volume":"23","author":"F Tascioglu","year":"2003","unstructured":"Tascioglu F, Oner C, Armagan O (2003) The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. Rheumatol Int 23(5):231\u2013235","journal-title":"Rheumatol Int"},{"issue":"11","key":"1504_CR124","first-page":"2395","volume":"28","author":"AB Cranney","year":"2001","unstructured":"Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR et al (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28(11):2395\u20132399","journal-title":"J Rheumatol"},{"issue":"2","key":"1504_CR125","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s002239900585","volume":"64","author":"LD Carbone","year":"1999","unstructured":"Carbone LD, Kaeley G, McKown KM, Cremer M, Palmieri G, Kaplan S (1999) Effects of long-term administration of methotrexate on bone mineral density in rheumatoid arthritis. Calcif Tissue Int 64(2):100\u2013101","journal-title":"Calcif Tissue Int"},{"key":"1504_CR126","doi-asserted-by":"publisher","first-page":"151952","DOI":"10.1016\/j.semarthrit.2022.151952","volume":"52","author":"N Ruffer","year":"2022","unstructured":"Ruffer N, Krusche M, Beil FT, Amling M, Kotter I, Rolvien T (2022) Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: a systematic review. Semin Arthritis Rheum 52:151952","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1504_CR127","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ard.2025.01.047","volume":"84","author":"B Hauser","year":"2025","unstructured":"Hauser B, Merriman A, Foley J, Golla J, McRorie E, Ralston SH (2025) Methotrexate continuation increases fracture risk in patients who sustained lower limb insufficiency fractures. Ann Rheum Dis 84(4):554\u2013561","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1504_CR128","first-page":"2299","volume":"29","author":"B Tengstrand","year":"2002","unstructured":"Tengstrand B, Hafstrom I (2002) Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. J Rheumatol 29(11):2299\u20132305","journal-title":"J Rheumatol"},{"issue":"5","key":"1504_CR129","first-page":"813","volume":"37","author":"OC Kwon","year":"2019","unstructured":"Kwon OC, Oh JS, Hong S, Lee CK, Yoo B, Kim YG (2019) Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide. Clin Exp Rheumatol 37(5):813\u2013819","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"1504_CR130","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/ard.2007.073817","volume":"67","author":"M Guler-Yuksel","year":"2008","unstructured":"Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM et al (2008) Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67(6):823\u2013828","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1504_CR131","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Van Staa","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48(11):3224\u20133229","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1504_CR132","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00198-021-05824-7","volume":"32","author":"N Guanabens","year":"2021","unstructured":"Guanabens N, Olmos JM, Hernandez JL, Cerda D, Hidalgo Calleja C, Martinez Lopez JA et al (2021) Vertebral fractures are increased in rheumatoid arthritis despite recent therapeutic advances: a case-control study. Osteoporos Int 32(7):1333\u20131342","journal-title":"Osteoporos Int"},{"issue":"3","key":"1504_CR133","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00198-024-07351-7","volume":"36","author":"N Laursen","year":"2025","unstructured":"Laursen N, Solling AS, Harslof T, Langdahl B (2025) Clinical experience with denosumab discontinuation. Osteoporos Int 36(3):435\u2013446","journal-title":"Osteoporos Int"},{"issue":"8","key":"1504_CR134","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103(8):2949\u20132957","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"1504_CR135","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543","journal-title":"N Engl J Med"},{"issue":"19","key":"1504_CR136","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434\u20131441","journal-title":"N Engl J Med"},{"issue":"9","key":"1504_CR137","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/art.40156","volume":"69","author":"DH Solomon","year":"2017","unstructured":"Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA et al (2017) Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 69(9):1741\u20131750","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1504_CR138","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.42617","volume":"75","author":"D Simon","year":"2023","unstructured":"Simon D, Minopoulou I, Kemenes S, Bayat S, Tascilar K, Mutlu MY et al (2023) Baricitinib improves bone properties and biomechanics in patients with rheumatoid arthritis: results of the prospective interventional BARE BONE Trial. Arthritis Rheumatol 75(11):1923\u20131934","journal-title":"Arthritis Rheumatol"},{"key":"1504_CR139","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-002995","author":"JA van der Pol","year":"2023","unstructured":"van der Pol JA, Akdemir G, van den Broek M, Dirven L, Kerstens P, Lems WF et al (2023) Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2023-002995","journal-title":"RMD Open"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01504-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:02:17Z","timestamp":1775883737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01504-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1504"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01504-y","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}